시장보고서

상품코드

1642607

유방암 액체생검 시장 : 성장, 전망, 경쟁 분석(2024-2032년)

Breast Cancer Liquid Biopsy Market - Growth, Future Prospects and Competitive Analysis, 2024 - 2032

발행일: 2024년 11월 | 리서치사:

Acute Market Reports | 페이지 정보: 영문 180 Pages | 배송안내 : 1-2일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

유방암 액체생검 시장은 2024년부터 2032년의 예측 기간 동안 CAGR 22.7%를 나타낼 것으로 예측됩니다. 유방암 액체생검 시장은 비침습적인 액체생검을 활용하여 혈액 샘플을 통해 유방암을 검출·모니터링하는 급속히 발전하고 있는 분야입니다. 이 방법은 전통적인 조직 생검보다 더 큰 진보를 가져오고 종양 역학에 대한 실시간 통찰력을 제공하며 맞춤 치료 전략을 가능하게 합니다. 암의 발견과 관리에 혁명을 가져올 가능성을 지닌 이 기술은 종양학 연구와 임상 응용의 최전선에 위치하고 있습니다.

촉진요인

유전체 기술의 진보

유전체 시퀀싱과 분석의 기술적 진보는 유방암 액체생검 시장을 견인하는 매우 중요한 요소입니다. 차세대 시퀀싱(NGS) 및 중합효소 연쇄반응(PCR) 기술이 고도화됨에 따라 유방암의 유전적 기반에 대한 깊은 인사이트를 얻을 수 있게 되어, 혈류 중의 미량의 종양 DNA의 검출이 가능하게 되었습니다. 이러한 진보는 액체생검의 감도와 특이성을 향상시킬 뿐만 아니라 조기 발견, 예후 예측, 치료 효과 및 내성 모니터링 등의 응용 가능성을 확대하고 있습니다. 유전체 기술의 지속적인 향상은 임상 현장에서 액체 생체 생물학의 채택 확대에서 그 역할을 뒷받침합니다.

비침습적 절차에 대한 수요 증가

비침습적 진단 절차에 대한 환자와 의료 제공업체의 선호도 증가도 유방암 액체생검 시장의 중요한 촉진요인입니다. 전통적인 조직 생검은 효과적이지만 침습적이며 종종 불쾌감과 잠재적 합병증을 유발합니다. 대조적으로, 액체 생검은 간단한 혈액 채취로 수행할 수 있는 낮은 침습 대안을 제공하여 환자의 스트레스와 위험을 완화합니다. 이러한 환자 친화적인 접근법은 종양 진행 및 치료에 대한 반응을 모니터링하는 데 필요한 반복 검사에 특히 유리하며, 액체 생검은 지속적인 질병 관리를 위한 매력적인 선택이 되고 있습니다.

유방암 유병률 상승

유방암 세계의 유병률 상승은 효과적인 진단·모니터링 툴에 대한 수요를 현저하게 부추겨 액체생검 시장을 밀어 올리고 있습니다. 유방암은 세계에서 가장 흔한 암 중 하나이며 조기 발견과 환자 결과 개선으로 이어지는 진단 기술의 진보가 시급합니다. 액체생검는 혈액 샘플로부터 암을 초기 단계에서 검출할 수 있는 도구를 제공함으로써 이 요구에 부응하여 시기 적절한 개입과 맞춤형 치료 계획을 촉진합니다. 세계 유방암 이환율 증가는 액체생검 솔루션의 개발과 채용의 유력한 촉진요인입니다.

억제요인

규제와 상환의 과제

유방암 액체생검 시장의 잠재력과 성장에도 불구하고 규제와 상환의 과제라는 큰 억제요인에 직면하고 있습니다. 액체 생체검사는 신규성이 높고 복잡하기 때문에 FDA와 같은 기관에서 규제 당국의 승인을 얻기에는 장애물이 높습니다. 게다가 액체생검의 사용과 해석에 대한 표준화된 지침이 없습니다는 것도 규제 문제에 박차를 가하고 있습니다. 보험 상환의 관점에서 액체생검의 보험 적용이 불충분하고 보험 상환 정책이 불분명하기 때문에 의료 제공업체가 이 기술을 채택하는 것을 망설일 수 있습니다. 이러한 규제와 상환의 문제는 시장의 성장과 보급을 늦추는 실질적인 장애가 되고 있습니다.

바이오마커를 이용한 시장 세분화

유방암 액체생검 시장은 순환 종양 세포(CTC), 무세포 DNA(cfDNA), 엑소좀, 기타 바이오마커 등의 바이오마커별로 세분화되어 있습니다. 그 중에서도 cfDNA는 미소잔존 병변이나 치료 저항성의 검출·모니터링에 있어서 임상적 유용성이 높기 때문에 수익면에서 선도하고 있습니다. cfDNA는 종양 유전학에 대한 신속하고 비침습적인 통찰력을 제공할 수 있기 때문에 임상 현장에서 선호됩니다. 또한 cfDNA는 시퀀싱 기술의 지속적인 발전과 임상 채택 증가로 인해 예측 기간 동안 가장 높은 연간 평균 성장률(CAGR)을 나타낼 전망입니다. 반면 CTC는 특히 전이 과정을 이해하는데 중요한 역할을 하지만, 분리와 분석과 관련된 기술적 과제로 인해 시장의 일부만을 차지하고 있습니다. 엑소좀은 종양의 거동과 치료에 대한 반응에 대한 통찰력을 제공할 수 있는 종합적인 분자 정보를 제공하기 때문에 인기를 끌고 있습니다. 단백질 및 대사산물을 포함한 다른 바이오마커는 연구가 진행되고 있으며 기존 바이오마커를 보완하여 보다 상세한 질병 프로파일링 및 치료 효과의 평가를 가능하게 할 수 있기 때문에 유망시되고 있습니다.

제품 및 서비스별 시장 세분화

유방암 액체생검 시장에서는 제품 및 서비스별로 키트 및 시약과 서비스가 세분화되고 있습니다. 키트 및 시약은 액체 생검 검사에 사용되는 기본 구성 요소이기 때문에 수익 측면에서 우위를 차지합니다. 이 분야는 환자의 치료 경과에 걸쳐 여러 단계의 검사를 실시하는 액체 생검 검사와 관련하여 자주 소비되고 정기적으로 구입되기 때문에 이익을 얻고 있습니다. 또한, 정확성과 효율성 향상을 목표로 하는 시약 및 키트의 지속적인 혁신이 높은 수익을 지원합니다. 반면 CAGR이 가장 높을 것으로 예상되는 것은 서비스입니다. 이 성장은 검사 수행, 데이터 분석 및 실용적인 통찰력을 포함한 종합적인 서비스 제공에 대한 선호도가 높아지게 되었습니다. 전문적인 진단 서비스 증가와 고급 액체생검 기술에 대응하기 위한 검사 시설의 능력 확장은 이 부문의 성장에 크게 기여하고 있습니다.

지리적 동향

유방암 액체생검 시장은 역동적인 지리적 동향을 보이고 있으며, 북미는 고급 의료 인프라, 암 검진에 대한 높은 의식, 주요 시장 기업의 존재로 현재 수익 면에서 선도하고 있습니다. 그러나 아시아태평양은 의료비 증가, 환자 의식 향상, 의료 시설 개선 등을 배경으로 2024년부터 2032년까지 가장 높은 연간 평균 성장률(CAGR)을 나타낼 것으로 예상되고 있습니다. 중국과 인도와 같은 국가에서 유방암 유병률이 높아지고 의료기술에 대한 투자가 증가하고 있는 것이 이 지역의 급성장을 뒷받침하고 있습니다. 유럽 역시 암 진단약에 관한 강력한 규제 프레임워크과 다액의 의료비에 힘입어 시장에서 큰 점유율을 유지하고 있습니다.

경쟁 동향

유방암 액체생검 시장은 Datar Cancer Genetics, Epic Sciences, F. Hoffmann-La Roche, Genes2me, Illumina, Menarini Silicon Biosystems, Myriad Genetics, OncoDNA, QIAGEN, Sysmex, System Biosciences, Thermo Fisher Scientific, Thermo Fisher Scientific 등이 있습니다. 이러한 기업들은 다양한 전략을 활용하여 시장 지위를 강화하고 수익원을 확대해 왔습니다. 2022년에는 이 기업들이 시장의 우위와 혁신적인 능력을 반영하여 많은 수익을 기록했습니다. 2024년부터 2032년까지의 예측 기간 동안 이러한 기업의 전략은 기술 혁신, 인수합병, 지리적 확대에 중점을 둘 것으로 예상됩니다. 예를 들어, 이들 기업 중 상당수는 액체생검의 정확성과 신뢰성을 높이기 위해 고급 유전체 기술을 통합하여 제품 라인을 강화하고 있습니다. 또한 아시아태평양과 라틴아메리카의 미개척 시장 등 세계적인 사업 확대를 목표로 하는 기업에 있어서 제휴와 협력 관계도 매우 중요합니다. 게다가 R&D 투자는 이러한 기업의 주요 전략으로, 새로운 바이오마커의 발견과 기존의 액체 바이오옵시 기술의 감도 향상을 이끌고자 합니다. 이러한 전략적 노력은 세계 시장 전체의 확대 동향과 일치하고 앞으로 수년간 이들 기업의 지속적인 성장과 경쟁 우위를 촉진할 것으로 예상됩니다.

소개
세계 유방암 액체생검 시장(금액 기준, 2022-2032년)
시장 역학
- 시장 성장 촉진요인
- 시장 성장 억제요인
- 주요 과제
- 주요 기회
성장 촉진요인과 억제요인의 영향 분석
See-Saw 분석
Porter's Five Forces 모델
- 공급자의 협상력
- 바이어의 협상력
- 대체품의 위협
- 신규 진입업자의 위협
- 경쟁 기업 간 경쟁 관계
PESTEL 분석
- 정치적 상황
- 경제적 상황
- 기술적 상황
- 법적 상황
- 사회적 상황

제5장 유방암 액체생검 시장 : 바이오마커별(2022-2032년)

시장 개요
성장·수익 분석 : 2023년 vs 2032년
시장 세분화
- 순환 종양 세포(CTC)
- 유리 DNA(cfDNA)
- 엑소좀
- 기타 바이오마커

제6장 유방암 액체생검 시장 : 제품 및 서비스별(2022-2032년)

시장 개요
성장·수익 분석 : 2023년 vs 2032년
시장 세분화
- 키트 및 시약
- 서비스

제7장 유방암 액체생검 시장 : 시료유형별(2022-2032년)

시장 개요
성장·수익 분석 : 2023년 vs 2032년
시장 세분화
- 피
- 소변
- 기타 유형의 시료

제8장 유방암 액체생검 시장 : 최종 용도별(2022-2032년)

시장 개요
성장·수익 분석 : 2023년 vs 2032년
시장 세분화
- 병원
- 암 연구센터
- 진단센터
- 학술연구기관

제9장 북미 유방암 액체생검 시장(2022-2032년)

시장 개요
유방암 액체생검 시장 : 바이오마커별(2022-2032년)
유방암 액체생검 시장 : 제품 및 서비스별(2022-2032년)
유방암 액체생검 시장 : 시료유형별(2022-2032년)
유방암 액체생검 시장 : 최종 용도별(2022-2032년)
유방암 액체생검 시장 : 지역별(2022-2032년)
- 북미
  - 미국
  - 캐나다
  - 기타 북미

제10장 영국·유럽연합의 유방암 액체생검 시장(2022-2032년)

시장 개요
유방암 액체생검 시장 : 바이오마커별(2022-2032년)
유방암 액체생검 시장 : 제품 및 서비스별(2022-2032년)
유방암 액체생검 시장 : 시료유형별(2022-2032년)
유방암 액체생검 시장 : 최종 용도별(2022-2032년)
유방암 액체생검 시장 : 지역별(2022-2032년)
- 영국·유럽연합
  - 영국
  - 독일
  - 스페인
  - 이탈리아
  - 프랑스
  - 기타 유럽

제11장 아시아태평양 유방암 액체생검 시장(2022-2032년)

시장 개요
유방암 액체생검 시장 : 바이오마커별(2022-2032년)
유방암 액체생검 시장 : 제품 및 서비스별(2022-2032년)
유방암 액체생검 시장 : 시료유형별(2022-2032년)
유방암 액체생검 시장 : 최종 용도별(2022-2032년)
유방암 액체생검 시장 : 지역별(2022-2032년)
- 아시아태평양
  - 중국
  - 일본
  - 인도
  - 호주
  - 한국
  - 기타 아시아태평양

제12장 라틴아메리카 유방암 액체생검 시장(2022-2032년)

시장 개요
유방암 액체생검 시장 : 바이오마커별(2022-2032년)
유방암 액체생검 시장 : 제품 및 서비스별(2022-2032년)
유방암 액체생검 시장 : 시료유형별(2022-2032년)
유방암 액체생검 시장 : 최종 용도별(2022-2032년)
유방암 액체생검 시장 : 지역별(2022-2032년)
- 라틴아메리카
  - 브라질
  - 멕시코
  - 기타 라틴아메리카

제13장 중동 및 아프리카 유방암 액체생검 시장(2022-2032년)

시장 개요
유방암 액체생검 시장 : 바이오마커별(2022-2032년)
유방암 액체생검 시장 : 제품 및 서비스별(2022-2032년)
유방암 액체생검 시장 : 시료유형별(2022-2032년)
유방암 액체생검 시장 : 최종 용도별(2022-2032년)
유방암 액체생검 시장 : 지역별(2022-2032년)
- 중동 및 아프리카
  - GCC
  - 아프리카
  - 기타 중동 및 아프리카

제14장 기업 프로파일

Datar Cancer Genetics
Epic Sciences
F. Hoffmann-La Roche
Genes2me
Illumina
Menarini Silicon Biosystems
Myriad Genetics
OncoDNA
QIAGEN
Sysmex
System Biosciences
Thermo Fisher Scientific
Twist Bioscience
기타 주요 기업

KTH 25.02.21

The breast cancer liquid biopsy market is expected to grow at a CAGR of 22.7% during the forecast period of 2024 to 2032. Breast cancer liquid biopsy market is a rapidly evolving field that utilizes non-invasive liquid biopsies to detect and monitor breast cancer through blood samples. This method offers a significant advancement over traditional tissue biopsies, providing real-time insights into tumor dynamics and allowing for personalized treatment strategies. The technology's potential to revolutionize cancer detection and management has positioned it at the forefront of oncology research and clinical application.

Drivers

Advancements in Genomic Technologies

Technological advancements in genomic sequencing and analysis have been pivotal in driving the breast cancer liquid biopsy market. As next-generation sequencing (NGS) and polymerase chain reaction (PCR) techniques have become more sophisticated, they offer deeper insights into the genetic basis of breast cancer, enabling the detection of minute quantities of tumor DNA in the bloodstream. These advancements have not only enhanced the sensitivity and specificity of liquid biopsies but have also broadened their potential applications, including early detection, prognosis, and monitoring of therapeutic efficacy and resistance. The continuous improvements in genomic technologies underscore their role in the growing adoption of liquid biopsies in clinical settings.

Growing Demand for Non-Invasive Procedures

The increasing preference for non-invasive diagnostic procedures among both patients and healthcare providers is another significant driver for the breast cancer liquid biopsy market. Traditional tissue biopsies, while effective, are invasive and often lead to discomfort and potential complications. In contrast, liquid biopsies offer a minimally invasive alternative that can be performed with a simple blood draw, reducing patient stress and risk. This patient-friendly approach is particularly advantageous for repeated testing required in monitoring tumor progression and response to treatment, making liquid biopsies an attractive option for continuous disease management.

Rising Prevalence of Breast Cancer

The rising global prevalence of breast cancer significantly fuels the demand for effective diagnostic and monitoring tools, boosting the liquid biopsy market. With breast cancer being one of the most common cancers worldwide, there is an urgent need for advancements in diagnostic techniques that can lead to earlier detection and improved patient outcomes. Liquid biopsies meet this need by providing a tool that can detect cancer at its earliest stages from a blood sample, facilitating timely intervention and personalized treatment plans. The increasing incidence of breast cancer globally is a compelling driver for the development and adoption of liquid biopsy solutions.

Restraint

Regulatory and Reimbursement Challenges

Despite the potential and growth of the breast cancer liquid biopsy market, it faces significant restraints with regulatory and reimbursement challenges. The novelty and complexity of liquid biopsy tests pose hurdles in gaining regulatory approvals from bodies like the FDA, as these agencies require extensive validation of the tests' clinical utility and accuracy before they can be broadly implemented. Furthermore, the lack of standardized guidelines for the use and interpretation of liquid biopsies adds to the regulatory challenges. On the reimbursement front, insufficient coverage and unclear reimbursement policies for liquid biopsies can deter healthcare providers from adopting this technology, as the financial costs of these advanced tests are often higher than traditional methods. These regulatory and reimbursement issues are substantial obstacles that slow the market's growth and widespread adoption.

Market Segmentation by Biomarkers

The breast cancer liquid biopsy market is segmented by biomarkers, including Circulating Tumor Cells (CTCs), Cell-free DNA (cfDNA), Exosomes, and Other Biomarkers. Among these, cfDNA leads in revenue generation due to its high clinical utility in detecting and monitoring minimal residual disease and treatment resistance. Its ability to provide rapid, non-invasive insights into tumor genetics makes cfDNA a preferred choice in clinical settings. Furthermore, cfDNA is projected to exhibit the highest Compound Annual Growth Rate (CAGR) over the forecast period, driven by continuous advancements in sequencing technologies and increasing clinical adoption. On the other hand, CTCs also play a crucial role, particularly in understanding metastatic processes, though they capture a smaller portion of the market due to the technical challenges associated with their isolation and analysis. Exosomes are gaining traction as they provide comprehensive molecular information that potentially offers insights into tumor behavior and response to therapy. The segment of Other Biomarkers, which includes proteins and metabolites, shows promise due to ongoing research and potential to complement existing biomarkers for a more detailed disease profiling and treatment efficacy evaluation.

Market Segmentation by Products & Services

In the breast cancer liquid biopsy market, segmentation by Products & Services includes Kits & Reagents and Services. Kits & Reagents dominate in terms of revenue, as they are the foundational components used in liquid biopsy tests. This segment benefits from the frequent consumption and recurring purchases associated with liquid biopsy procedures, which involve multiple stages of testing over a patient's treatment course. Additionally, the ongoing innovation in reagents and kits, aimed at enhancing accuracy and efficiency, supports their high revenue generation. Meanwhile, Services are expected to witness the highest CAGR. This growth is fueled by the increasing preference for comprehensive service offerings that include test execution, data analysis, and actionable insights, which are highly valued in clinical settings for making informed treatment decisions. The rise in specialized diagnostic services and the expansion of laboratory capabilities to accommodate advanced liquid biopsy technologies contribute significantly to the growth of this segment.

Geographic Trends

The breast cancer liquid biopsy market demonstrates dynamic geographic trends, with North America currently leading in terms of revenue due to its advanced healthcare infrastructure, high awareness about cancer screenings, and the presence of key market players. However, Asia-Pacific is expected to exhibit the highest Compound Annual Growth Rate (CAGR) from 2024 to 2032, driven by rising healthcare expenditures, increasing patient awareness, and improving healthcare facilities. The growing prevalence of breast cancer in countries like China and India, coupled with increasing investments in healthcare technologies, fuels the rapid growth in this region. Europe also maintains a significant share in the market, supported by its strong regulatory frameworks for cancer diagnostics and substantial healthcare spending.

Competitive Trends

In terms of competitive trends, the market sees robust participation from companies like Datar Cancer Genetics, Epic Sciences, F. Hoffmann-La Roche, Genes2me, Illumina, Menarini Silicon Biosystems, Myriad Genetics, OncoDNA, QIAGEN, Sysmex, System Biosciences, Thermo Fisher Scientific, and Twist Bioscience. These entities have leveraged various strategies to solidify their market positions and expand their revenue streams. In 2022, these companies reported substantial revenues, reflecting their dominance and innovative capabilities within the market. Their strategies for the forecast period of 2024 to 2032 are expected to focus on technological innovations, mergers and acquisitions, and geographic expansion. For instance, many of these firms are enhancing their product lines with integrations of advanced genomic technologies to increase the accuracy and reliability of liquid biopsies. Partnerships and collaborations are also crucial as companies aim to expand their global footprints, particularly in untapped markets within Asia-Pacific and Latin America. Moreover, investment in research and development is a key strategy for these companies, aiming to lead in the discovery of novel biomarkers and improve the sensitivity of existing liquid biopsy techniques. These strategic efforts are anticipated to drive the continued growth and competitive edge of these companies in the upcoming years, aligning with the overall expansion trends seen across the global market.

Historical & Forecast Period

This study report represents an analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Breast Cancer Liquid Biopsy market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Breast Cancer Liquid Biopsy market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

Market Segmentation
Biomarkers

Circulating tumor cells (CTCs)

Cell-free DNA (cfDNA)

Exosomes

Other biomarkers

Products & Services

Kits & reagents

Services

Sample Type

Blood

Urine

Other sample types

End Use

Hospitals

Cancer research centers

Diagnostic centers

Academic and research institutes

Region Segment (2022-2032; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Breast Cancer Liquid Biopsy market?
What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2032.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Breast Cancer Liquid Biopsy market?
Which is the largest regional market for Breast Cancer Liquid Biopsy market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Breast Cancer Liquid Biopsy market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Breast Cancer Liquid Biopsy market worldwide?

1. Preface

1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted

2. Executive Summary

2.1. Market Snapshot: Global Breast Cancer Liquid Biopsy Market
2.2. Global Breast Cancer Liquid Biopsy Market, By Biomarkers, 2023 (US$ Million)
2.3. Global Breast Cancer Liquid Biopsy Market, By Products & Services, 2023 (US$ Million)
2.4. Global Breast Cancer Liquid Biopsy Market, By Sample Type, 2023 (US$ Million)
2.5. Global Breast Cancer Liquid Biopsy Market, By End Use, 2023 (US$ Million)
2.6. Global Breast Cancer Liquid Biopsy Market, By Geography, 2023 (US$ Million)
2.7. Attractive Investment Proposition by Geography, 2023

3. Breast Cancer Liquid Biopsy Market: Competitive Analysis

3.1. Market Positioning of Key Breast Cancer Liquid Biopsy Market Vendors
3.2. Strategies Adopted by Breast Cancer Liquid Biopsy Market Vendors
3.3. Key Industry Strategies

4. Breast Cancer Liquid Biopsy Market: Macro Analysis & Market Dynamics

4.1. Introduction
4.2. Global Breast Cancer Liquid Biopsy Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
- 4.6.1. Supplier Power
- 4.6.2. Buyer Power
- 4.6.3. Threat Of Substitutes
- 4.6.4. Threat Of New Entrants
- 4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
- 4.7.1. Political Landscape
- 4.7.2. Economic Landscape
- 4.7.3. Technology Landscape
- 4.7.4. Legal Landscape
- 4.7.5. Social Landscape

5. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)

5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
- 5.3.1. Circulating tumor cells (CTCs)
- 5.3.2. Cell-free DNA (cfDNA)
- 5.3.3. Exosomes
- 5.3.4. Other biomarkers

6. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)

6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
- 6.3.1. Kits & reagents
- 6.3.2. Services

7. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)

7.1. Market Overview
7.2. Growth & Revenue Analysis: 2023 Versus 2032
7.3. Market Segmentation
- 7.3.1. Blood
- 7.3.2. Urine
- 7.3.3. Other sample types

8. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

8.1. Market Overview
8.2. Growth & Revenue Analysis: 2023 Versus 2032
8.3. Market Segmentation
- 8.3.1. Hospitals
- 8.3.2. Cancer research centers
- 8.3.3. Diagnostic centers
- 8.3.4. Academic and research institutes

9. North America Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)

9.1. Market Overview
9.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
9.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
9.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
9.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
9.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
- 9.6.1.North America
  - 9.6.1.1. U.S.
    - 9.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 9.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 9.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 9.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  - 9.6.1.2. Canada
    - 9.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 9.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 9.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 9.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  - 9.6.1.3. Rest of North America
    - 9.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 9.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 9.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 9.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

10. UK and European Union Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)

10.1. Market Overview
10.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
10.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
10.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
10.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
10.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
- 10.6.1.UK and European Union
  - 10.6.1.1. UK
    - 10.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 10.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 10.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 10.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  - 10.6.1.2. Germany
    - 10.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 10.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 10.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 10.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  - 10.6.1.3. Spain
    - 10.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 10.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 10.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 10.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  - 10.6.1.4. Italy
    - 10.6.1.4.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 10.6.1.4.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 10.6.1.4.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 10.6.1.4.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  - 10.6.1.5. France
    - 10.6.1.5.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 10.6.1.5.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 10.6.1.5.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 10.6.1.5.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  - 10.6.1.6. Rest of Europe
    - 10.6.1.6.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 10.6.1.6.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 10.6.1.6.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 10.6.1.6.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

11. Asia Pacific Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)

11.1. Market Overview
11.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
11.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
11.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
11.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
11.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
- 11.6.1.Asia Pacific
  - 11.6.1.1. China
    - 11.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 11.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 11.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 11.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  - 11.6.1.2. Japan
    - 11.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 11.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 11.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 11.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  - 11.6.1.3. India
    - 11.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 11.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 11.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 11.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  - 11.6.1.4. Australia
    - 11.6.1.4.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 11.6.1.4.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 11.6.1.4.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 11.6.1.4.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  - 11.6.1.5. South Korea
    - 11.6.1.5.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 11.6.1.5.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 11.6.1.5.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 11.6.1.5.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  - 11.6.1.6. Rest of Asia Pacific
    - 11.6.1.6.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 11.6.1.6.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 11.6.1.6.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 11.6.1.6.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

12. Latin America Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)

12.1. Market Overview
12.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
12.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
12.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
12.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
12.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
- 12.6.1.Latin America
  - 12.6.1.1. Brazil
    - 12.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 12.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 12.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 12.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  - 12.6.1.2. Mexico
    - 12.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 12.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 12.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 12.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  - 12.6.1.3. Rest of Latin America
    - 12.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 12.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 12.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 12.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

13. Middle East and Africa Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)

13.1. Market Overview
13.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
13.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
13.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
13.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
13.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
- 13.6.1.Middle East and Africa
  - 13.6.1.1. GCC
    - 13.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 13.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 13.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 13.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  - 13.6.1.2. Africa
    - 13.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 13.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 13.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 13.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  - 13.6.1.3. Rest of Middle East and Africa
    - 13.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
    - 13.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
    - 13.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
    - 13.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

14. Company Profile

14.1. Datar Cancer Genetics
- 14.1.1. Company Overview
- 14.1.2. Financial Performance
- 14.1.3. Product Portfolio
- 14.1.4. Strategic Initiatives
14.2. Epic Sciences
- 14.2.1. Company Overview
- 14.2.2. Financial Performance
- 14.2.3. Product Portfolio
- 14.2.4. Strategic Initiatives
14.3. F. Hoffmann-La Roche
- 14.3.1. Company Overview
- 14.3.2. Financial Performance
- 14.3.3. Product Portfolio
- 14.3.4. Strategic Initiatives
14.4. Genes2me
- 14.4.1. Company Overview
- 14.4.2. Financial Performance
- 14.4.3. Product Portfolio
- 14.4.4. Strategic Initiatives
14.5. Illumina
- 14.5.1. Company Overview
- 14.5.2. Financial Performance
- 14.5.3. Product Portfolio
- 14.5.4. Strategic Initiatives
14.6. Menarini Silicon Biosystems
- 14.6.1. Company Overview
- 14.6.2. Financial Performance
- 14.6.3. Product Portfolio
- 14.6.4. Strategic Initiatives
14.7. Myriad Genetics
- 14.7.1. Company Overview
- 14.7.2. Financial Performance
- 14.7.3. Product Portfolio
- 14.7.4. Strategic Initiatives
14.8. OncoDNA
- 14.8.1. Company Overview
- 14.8.2. Financial Performance
- 14.8.3. Product Portfolio
- 14.8.4. Strategic Initiatives
14.9. QIAGEN
- 14.9.1. Company Overview
- 14.9.2. Financial Performance
- 14.9.3. Product Portfolio
- 14.9.4. Strategic Initiatives
14.10. Sysmex
- 14.10.1. Company Overview
- 14.10.2. Financial Performance
- 14.10.3. Product Portfolio
- 14.10.4. Strategic Initiatives
14.11. System Biosciences
- 14.11.1. Company Overview
- 14.11.2. Financial Performance
- 14.11.3. Product Portfolio
- 14.11.4. Strategic Initiatives
14.12. Thermo Fisher Scientific
- 14.12.1. Company Overview
- 14.12.2. Financial Performance
- 14.12.3. Product Portfolio
- 14.12.4. Strategic Initiatives
14.13. Twist Bioscience
- 14.13.1. Company Overview
- 14.13.2. Financial Performance
- 14.13.3. Product Portfolio
- 14.13.4. Strategic Initiatives
14.14. Other Notable Players
- 14.14.1. Company Overview
- 14.14.2. Financial Performance
- 14.14.3. Product Portfolio
- 14.14.4. Strategic Initiatives